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Multiple myeloma (MM) is an incurable malignancy of anti-
body-producing clonal plasma cells. The mean life expectancy
of patients has remained at o3 years during the past few
decades. The introduction of a new generation drug regimens
including an immunomodulatory agent such as lenalidomide
(LEN) or a proteasome inhibitor such as bortezomib (BORT)
used alone or in combination with classical anti-MM drugs
melphalan (MEL), dexamethasone (DEX) or prednisone (PRED)
has signiﬁcantly improved the overall survival of MM
patients.
1,2 All treatment strategies, including multidrug regi-
mens, however, are eventually hampered by the development of
drug resistance.
3 Targeted immunotherapy, based on human
antibodies against relevant tumor antigens has shown to be a
feasible and highly promising approach in hematological
malignancies that can be effectively combined with chemother-
apy to further increase the potency of anti-tumor effects. For
instance in several B-cell malignancies, clinically approved
human antibodies against CD20 are now being successfully
combined with ﬂudarabine, cyclophosphamide or LEN.
4,5
Building on this knowledge and to achieve a similar goal in
the MM setting, we recently generated daratumumab (DARA), a
human CD38 antibody with broad-spectrum killing activity.
6
We have shown that DARA mediates strong lysis of MM cells via
CDC (complement-dependent cytotoxicity) as well as ADCC
(antibody-dependent cellular cytotoxicity), although the
potency of autologous ADCC was donor-dependent. In our
initial work to combine DARA with novel chemotherapeutics,
we have demonstrated that DARA-mediated cellular lysis of MM
cells is signiﬁcantly improved by LEN, mainly because of the
potent capacity of LEN to activate the effector cells of ADCC.
7
Current clinical practice, however, shows that the future of
successful MM treatment lies in the use of drug combination
regimens. It appears essential to identify regimens in which
individual components synergize to obtain the greatest achiev-
able effects. Therefore, we now explored the potential clinical
beneﬁt of combining targeted DARA therapy with newly
emerging multi-drug chemotherapy regimens. To this end, we
used a recently developed ex vivo ﬂow cytometry-based assay
platform,
7 which enables us to enumerate and subsequently
deduce the drug/antibody-mediated lysis of primary CD138
þ
MM cells directly in bone marrow samples from the MM
patients. The assays are performed with bone marrow mono-
nuclear cells (BM-MNC), thus without the need for separating
malignant cells from autologous effector cells and tumor-
supporting accessory cells, such as stromal cells. With this ex
vivo assay system, we ﬁrst addressed the beneﬁts of combining
DARA with both LEN and BORT, since not only LEN but also
BORT may enhance the therapeutic efﬁcacy of DARA by
sensitizing tumor cells for antibody-mediated lysis. In a series of
experiments, we incubated BM-MNC from 16 MM patients,
containing 2–20% malignant plasma cells, either with medium
alone or with combinations of LEN, BORT and DARA at
carefully selected individual concentrations inducing half-
maximal lysis of MM cells. An antibody against an irrelevant
antigen (Keyhole Limpet Hemocyanin (KLH)) was used as an
isotype control. After 48h, we harvested the cells, labeled them
with a monoclonal CD138 antibody and enumerated the
surviving CD138
þ MM cells using single-platform ﬂow
cytometry, to assess the percentage of MM cell lysis in each
sample (Figure 1a) relative to that obtained with the control
antibody KLH, which induced negligible MM cell lysis
(data not shown). LEN and BORT alone or in combination
caused low to moderate lysis of MM cells (mean lysis 10%, 18%
and 25%, respectively). Addition of DARA signiﬁcantly
increased the MM cell lysis by more than twofold in all
combinations (P¼0.001). The highest MM cell lysis was
observed with the triple LEN-BORT-DARA combination.
Notably, combination with DARA seemed to improve MM cell
lysis especially in the samples that poorly responded to LEN and
BORT (MM cell lysis o30%; Figure 1a). To evaluate this, we
analyzed the data of LEN/BORT high and low responders
separately (Figures 1b and c). A signiﬁcant improvement of MM
cell lysis by DARA was observed in the LEN/BORT low-
responder subset particularly (Figure 1c) and the effect was
synergistic. This group included cells from ﬁve patients who had
been treated in the clinic with LEN and/or BORT without
success (Figure 1d).
Interestingly, the synergy between DARA and LEN/BORT
treatment was also apparent for cells from the ﬁve LEN/BORT-
resistant patients (Figure 1d, as illustrated by the fact that
observed levels of MM cell lysis with DARA/LEN/BORT
treatment were signiﬁcantly higher than the expected levels of
MM cell lysis, calculated on the assumption that there was no
treatment interaction). Although we have only been able to
evaluate a small number of samples from resistant patients to
date, this remarkable synergy suggests the maintenance of anti-
tumorigenic properties of LEN and BORT, despite the develop-
ment of drug resistance. Taken together, these results indicate
the potential clinical beneﬁts of combining DARA with these
two novel anti-MM agents and warrant further investigation
even in patients who are low responders or have become
resistant to the latter drugs.
After showing the potential beneﬁts of combining DARA with
LEN and BORT, our further investigation focused on two
recently introduced and so far the most successful ﬁrst-line
combination therapies based on these two novel agents, namely
the triple combinations of LEN, BORT, DEX, abbreviated as
RVD, and of MEL, PRED, BORT, abbreviated as MPV. To assess
the impact of combining DARA with these combination
chemotherapies, we prepared cocktails of these agents, by
mixing them at concentrations causing ±30% of the maximal
lytic effect on various MM cell lines (data not shown). We then
incubated BM-MNC of MM patients with serial dilutions of these
cocktails alone or in the presence of DARA and assessed MM
cell lysis. As expected, cocktails of RDV (Figure 2a) as well as
MPV (Figure 2b) induced dose-dependent lysis of MM cells.
Addition of DARA to both RDV and MPV signiﬁcantly increased
the treatment efﬁcacy by almost doubling the lysis levels
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that targeted immunotherapy of MM by DARA holds a signiﬁcant
potential to improve the clinical outcome of currently available
novel combination therapies.
Recent studies have indicated that combination of multiple
drugs are superior over single- or double-agent combinations.
2
Addition of new drugs to the available regimens can
mediate their clinical beneﬁt because of the induction of a
higher rate of initial complete responses, which in turn improves
the relapse free and overall survival.
8 Contingent on the
premise that the combined agents have non-overlapping and
synergistic mechanisms of actions, immediate and effective
targeting of tumors with multiple agents appears a successful
strategy to improve the clinical outcome of MM therapy.
Indeed, such a strategy is in full agreement with the emerging
concept that the genetic signature of MM, and consequently,
the individual patient’s susceptibility to a speciﬁc agent
will be highly heterogeneous and this eventually may lead to
drug resistance. Nevertheless, the complete response rate of
the best chemotherapeutic combinations is currently o50%,
and all current combination therapies eventually induce
drug resistance.
2,9 In this respect, DARA, with its immediate
and effective cell-mediated cytotoxic effects against MM
cells, and the observed remarkable synergy with LEN/BORT
even in LEN/BORT refractory patients, may potentially
improve the achievement of ﬁrst CR in MM when combined
with these agents either alone or in multidrug chemotherapy
regimens. In conclusion, our study, in which we demonstrate
the potential beneﬁts of combining DARA-mediated targeted
therapy with newly emerging chemotherapy options,
warrants the evaluation of this approach in MM in clinical
phase I/II trials.
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Figure 1 Addition of DARA to BORT-LEN signiﬁcantly increases the MM cell lysis in BM-MNC of MM patients, particularly in LEN/BORT low
responder or refractory patients. (a) BM-MNC from MM patients (n¼16), containing 2–20% CD138
þ MM cells as detected by ﬂow cytometry
were incubated with LEN (3mM), BORT (3nM) and DARA (10mg/ml) alone or in combination for 48h in RPMIþ 10% fetal bovine serum in 96-well
u bottom plates in fully humidiﬁed incubators at 371C, 5% CO2-air mixture. Surviving MM cells were enumerated by the single-platform
ﬂuorescence-activated cell sorting analysis of CD138
þ cells in the presence of Tru-Count beads (Beckman Coulter, Miami, FL, USA). Percentage
lysis of MM cells in LEN, DARA and LENþDARA-treated conditions were calculated using the MM survival of wells treated with the control KLH
antibody alone. Differences between indicated groups were tested for signiﬁcance in repeated measures analysis of variance (ANOVA), using
Bonferonni’s post-hoc multiple comparison tests with two-tailed 95% conﬁdence intervals. In b–d, data are analyzed for low LEN/BORT
responders, high LEN/BORT responders and LEN/BORT refractory patients, respectively.
aP-values were calculated using a repeated measures
ANOVA.
bP-values were calculated by a paired t-test.
cExpected values were calculated to test the null hypothesis that there is no synergism
between DARA and LEN/BORT using the following formula: % expected lysis¼100 %survival after DARA %survival after LEN/BORT.
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Figure 2 DARA increases response against MM in triple chemother-
apy treatments. BM-MNC form patients (n¼7) were incubated
with increasing dilutions of a cocktail of (a) LEN, BORT and DEX
(1  dilution contains: 1mM LEN, 1nM BORT and 1mM DEX) or with a
cocktail of (b) MEL, PRED, BORT (1  dilution contains 1mM MEL,
1mM PRED and 1nM BORT) in the presence or absence of DARA
(10mg/ml) for 48h. Surviving MM cells were enumerated by
ﬂuorescence-activated cell sorting analysis of CD138þ cells.
P-values were calculated by a paired t-test.
nPo0.05,
nnnPo0.001.
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